Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal, Randomized, Single-dose, Open-label, Four-Way Crossover, BE Study of TAH3311 (Apixaban ODF) Under Fasted and Fed Conditions vs. ELIQUIS® Oral Tablet Under Fasted Condition in Healthy Volunteers

NCT06689436 is registered in ClinicalTrials.gov with TAHO Pharmaceuticals Ltd. as lead sponsor.

NCT NCT06689436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06689436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal, Randomized, Single-dose, Open-label, Four-Way Crossover, BE Study of TAH3311 (Apixaban ODF) Under Fasted and Fed Conditions vs. ELIQUIS® Oral Tablet Under Fasted Condition in Healthy Volunteers
Lead sponsor
TAHO Pharmaceuticals Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2024
Completion date
April 1, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

enteral feeding, intermittent fasting, random allocation